Dubourg J, Fouqueray P, Quinslot D, Grouin JM, et al. Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): a 52-week open-label, multicenter phase 3 trial. Diabetes Obes Metab 2021 Dec 6. doi: 10.1111/dom.14613.
PMID: 34866306